Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis: how much is it true?
Kilickap
S
S
Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Cumhuriyet University, Sivas. Electronic address: skilickap@yahoo.com.
Arslan
C
C
Department of Medical Oncology, Hacettepe University Institute of Oncology, Ankara, Turkey.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000188:drug therapy*; D002277:Carcinoma / Q000175:diagnosis* / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D015251:Epirubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D017239:Paclitaxel / Q000008:administration & dosage; D011300:Preoperative Care / Q000379:methods; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome
D043823:Taxoids; D015251:Epirubicin; D005047:Etoposide; D017239:Paclitaxel; D002945:Cisplatin